FDA IND Review: Regulations and Challenges

Slides:



Advertisements
Similar presentations
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Advertisements

The Radioactive Drug Research Committee Approval Process for Tracer Use Anthony F. Shields, M.D., Ph.D. Karmanos Cancer Institute Wayne State University.
Paula M. Jacobs, Ph.D. SAIC Frederick Cancer Imaging Program/DCTD/NCI/NIH September 5, 2006 Phase 0 Trials in Oncologic Drug Development DCTD Phase 0 Workshop.
Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development An Introduction.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Case Studies.
1 Pharmacology/Toxicology information to submit an IND for an anticancer drug.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.
Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.
Mitochondrial Manipulation Technologies: Preclinical Considerations
Pediatric Ethics Subcommittee of Pediatric Advisory Committee, September 10, 2004 Analysis of Research Protocols Involving Children: Combining Subparts.
Expanded Access Programs for Drugs and Biologics _________________________________________________________ Richard Klein Office of Health and Constituent.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Special Topics in IND Regulation
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
REGULATORY ISSUES IN HIV CURE RESEARCH HIV Cure Research Training Curriculum Regulatory Issues Module by: Damon Deming, Ph.D. FDA Division of Antiviral.
1 Overview: Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies Raj K. Puri, M.D., Ph.D. Director, DCGT Office of Cellular,
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
U of Arizona Innovation Conference 20 September 2011 Marlene E. Haffner, MD, MPH Haffner Associates, LLC.
Cellular Therapies for Cardiac Diseases – FDA Preclinical Perspective Richard D. McFarland Ph.D., M.D. CBER/OCTGT/DCEPT BRMAC # 37 March 18-19, 2004.
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
1 FDA Draft Guidance: Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapies John Hyde, PhD, MD OCTGT / CBER Cellular,
Cellular Tissue and Gene Therapies Research Site Visit Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies September 29,
Office of Cellular Tissue and Gene Therapies Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Cellular, Tissue, and.
Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.
Investigational New Drug Application 21 CFR Part 312 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International
Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.
Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Case Studies.
Stages of drug development
1 First-in-Human Trials of Cellular Therapies John Hyde, Ph.D., M.D. Office of Cellular, Tissue, and Gene Therapies Division of Clinical Evaluation and.
Yesterday, today, and tomorrow
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
Associate Director for Research, OCTGT
Investigational New Drug Application (IND)
Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP.
Animal Models for Porcine Xenotransplantation Products Intended to Treat Type 1 Diabetes or Acute Liver Failure CTGTAC #47 May 14, 2009.
Exploratory IND Studies
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
1/33.  What is INDA ?  Types of INDAs  Objectives of INDAs  Format & Contents of an INDA  IND Safety reports  IND Annual Reports  IND Review Process.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
History of Pediatric Labeling
FDA Office of Orphan Products Development
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
Chief, Gene Therapy Branch
The Regulatory Science of Regenerative Medicine Celia M. Witten, Ph.D., M.D., Director Office of Cellular, Tissue and Gene Therapies Center for Biologics.
21 CFR Toby A. Silverman, M.D. Branch Chief, Clinical Review Branch Division of Hematology, Office of Blood December 14, 2006.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
EXCEPTION FROM INFORMED CONSENT IN CPR DEVICE TRIALS: PROTECTION OF PATIENTS’ RIGHTS Circulatory System Devices Panel Meeting September 21, 2004 Elisa.
1 IND Applications for Academic Clinical Investigations John Marler, MD US Food and Drug Administration New Hampshire Avenue White Oak, MD
Drug Development Process Stages involved in Regulating Drugs
Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.
Clinical Investigator Training Course
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
Pre-Investigational New Drug (pre-IND) Meeting with FDA
FDA’s IDE Decisions and Communications
Bozeman Health Clinical Research
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Speeding access to therapies
Intermediate-Size Patient Populations INDs: What Are They, When Should They Be Used, and Who May Apply for Them?” Richard Klein, Former Director, FDA.
IND Review Process Seoul National University
Ethical Considerations for Pediatric Clinical Investigations
Presentation transcript:

FDA IND Review: Regulations and Challenges Wilson W. Bryan, M.D. FDA / CBER / OCTGT wilson.bryan@fda.hhs.gov Workshop on Cell and Gene Therapy Clinical Trials in Pediatric Populations North Bethesda, Maryland November 2, 2010

FDA / CBER / OCTGT Office of Cellular, Tissue and Gene Therapies Celia M. Witten, Ph.D., M.D., Director Stephanie Simek, Ph.D., Deputy Director Richard McFarland, Ph.D., M.D., Associate Director for Policy Suzanne Epstein, Ph.D., Associate Director for Research Regulatory Project Management Patrick Riggins, Ph.D., Director Division of Cellular and Gene Therapies (DCGT) Raj Puri, M.D., Ph.D., Director Kimberly Benton, Ph.D., Deputy Director Division of Human Tissue Products (DHT) Ellen Lazarus, M.D., Director Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT) Mercedes A. Serabian, M.S., DABT, Pharmacology/Toxicology Branch Chief Wilson W. Bryan, M.D., Clinical Evaluation Branch Chief

Pediatric Protocols in OCTGT 113 active pediatric trial protocols 19 “first-in-man” protocols Increase in pediatric protocols submitted to OCTGT over the past several years

OCTGT Pediatric Trial Therapies and Indications By Treatment Indication Oncology – 56 Medicine – 57 By Therapy Cellular 60% Gene 27% Combination 4% (Engineered Tissues) Other 9%

FDA IND Review: Regulations and Challenges: Outline Therapeutic Development Objective Process Regulatory Process IND Review Clinical Hold Pediatric Studies CFR Subpart D Regulatory Challenges

Therapeutic Development Objective: Provide evidence that drugs (including biologics, such as cell and gene therapies) are safe and effective for a specific indication.

Therapeutic Development Process Knowledge of the disease process Drug discovery Nonclinical (animal) study objectives: Toxicity, biodistribution, carcinogenicity, proof-of-principle Guide design (including dosing, population, and monitoring) of subsequent Phase 1 studies Phase 1 objectives: Safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, (and activity / efficacy, if feasible) Guide dosing and monitoring of subsequent Phase 2 studies Phase 2 objectives: Determine dose, route, regimen, population, endpoints, and estimated magnitude of effect Guide design of subsequent confirmatory (Phase 3) studies Phase 3 objectives: Evidence of efficacy and safety to support a marketing application (New Drug Application (NDA) or Biologics Licensing Application (BLA))

Regulatory Process Investigational New Drug application (IND) Review Team Project Manager Chemistry, Manufacturing, and Controls (CMC) Nonclinical Pharmacology / Toxicology Clinical Others (e.g., statistics, epidemiology, site inspectors, patient representative) Objective: FDA’s primary objectives in reviewing an IND are, in all phases of the investigation, to assure the safety and rights of subjects … (21 CFR 312.22(a))

Regulatory Process Investigational New Drug application (IND) Clinical Hold: A clinical hold is an order issued by FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation (21 CFR 312.42 (a)).

Regulatory Process Clinical Hold: FDA may place a proposed or ongoing Phase 1 investigation on clinical hold if it finds that (21 CFR 312.42(b)): Human subjects are or would be exposed to an unreasonable and significant risk of illness or injury; (ii) The clinical investigators named in the IND are not qualified …; (iii) The investigator brochure is misleading, erroneous, or materially incomplete; (iv) The IND does not contain sufficient information … to assess the risks to subjects of the proposed studies.

Regulatory Process Most common hold issues, particularly for Phase 1 (and Phase 2) studies: Human subjects are or would be exposed to an unreasonable and significant risk of illness or injury. (iv) The IND does not contain sufficient information … to assess the risks to subjects of the proposed studies.

Regulatory Process Human subjects are or would be exposed to an unreasonable and significant risk of illness or injury; The assessment of whether a risk is reasonable includes consideration of available in vitro, animal, and clinical data, the study objectives, and the population (e.g., disease severity; prognosis; availability of alternative therapies) being studied. For example, risks that are acceptable in a population with a late-stage malignancy might be unacceptable in a presymptomatic population with a genetic defect.

Regulatory Process: Phase 1 – Review Considerations Study design Proof-of-concept Is there sufficient evidence of potential efficacy to justify the risks? Population: Do the potential benefits justify the risks for the study subjects in the experimental arm? and in the control arm (if any)? Would a different study population have lower risk and still achieve the study objectives? Stopping rules (and / or Data Safety Monitoring Board (DSMB)) Are appropriate controls in place to stop the study if adverse events suggest that there is an unreasonable risk?

Regulatory Process: Phase 1 – Review Considerations Dose Starting dose Maximum dose Are the proposed starting dose and the proposed maximum dose justified by the available nonclinical and/or clinical data? Rate of dose escalation Is the rate of dose escalation acceptable, considering the available nonclinical and/or clinical data? Regimen Is the regimen appropriate for the stage of drug development?

Regulatory Process: Phase 1 – Review Considerations Monitoring Intervals (both intra-cohort and inter-cohort) TGN 1412 experience Are these intervals justified by the available nonclinical and clinical data? What are the appropriate intervals when there is concern about long-term toxicity? Procedures Are monitoring procedures sufficiently sensitive and frequent? Do the monitoring procedures have unacceptable risks? Duration of follow-up What duration of follow-up is necessary when primary toxicity may be long-term, as in some cell and gene therapy studies? Guidance for Industry: Gene Therapy Clinical Trials – Observing Subjects for Delayed Adverse Events

Pediatric Studies: CFR Subpart D Subpart D § 50.52: Clinical investigations involving greater than minimal risk but presenting the prospect of direct benefit to individual subjects. OCTGT believes that most cell and gene therapy trials have more than a minor increase over minimal risk. To provide evidence of the prospect of direct benefit, OCTGT often asks IND sponsors to provide proof-of-concept data from nonclinical and / or previous human studies. If a cell or gene therapy study is not approvable under §50.52, the study might be approvable under § 50.54. However, OCTGT does not refer the study for consideration under § 50.54.

Pediatric Studies: CFR Subpart D The agency encourages IRBs considering referring a clinical investigation under § 50.54 first to discuss with the sponsor whether there are appropriate modifications to the protocol that would allow the clinical investigation to be approved under another provision of Subpart D. IRBs should send referrals under 21 CFR 50.54 of clinical investigations regulated by FDA to FDA's Office of Pediatric Therapeutics, which will coordinate the review. FDA’s guidance on § 50.54 referrals may be located at http://www.fda.gov/RegulatoryInformation/Guidances/ucm127541.htm

Regulatory Challenges in Pediatric Clinical Trials: For the sponsor Minimize risks while maintaining prospect of direct benefit and acceptable risk-benefit ratio What constitutes sufficient evidence of a prospect of direct benefit (i.e., proof-of-concept (POC) data)? Should nonclinical POC studies be replicated by independent groups? What is the appropriate study population? Is there an adult population that would be sufficiently informative, with an acceptable risk-benefit ratio? What study procedures (e.g., MRI, lumbar puncture) are acceptable? Consider the risk of the procedure, the benefit (if any) of the procedure to the subject, and the value of the resulting data (benefit of generalizable knowledge).

Regulatory Challenges in Pediatric Clinical Trials: For the sponsor For pediatric studies, OCTGT asks the sponsor to describe the following: how the study meets the requirements of Subpart D why the study of children is scientifically necessary

Regulatory Challenges in Pediatric Clinical Trials: For the FDA Can study risks be sufficiently minimized so that it would be appropriate for a pediatric study to be a first-in-man study for a new experimental cell or gene therapy? When adults are studied before proceeding with a study in children, review considerations include: The number of adults The duration of monitoring of adult subjects before proceeding in children The data necessary to provide sufficient evidence of safety and/or proof-of-concept in adults before proceeding in children

Regulatory Challenges in Pediatric Clinical Trials: For the IRB Do some IRBs defer assessment of the scientific and/or ethical/human subject protection issues to other entities (e.g., FDA; NIH Recombinant DNA Advisory Committee (RAC))? How do IRBs determine whether early stage gene or cell transfer studies have a prospect of direct benefit?

Contact Information wilson.bryan@fda.hhs.gov OCTGT Regulatory Issues Patrick Riggins, Ph.D. Regulatory Management Branch Chief Patrick.riggins@fda.hhs.gov 301-827-5366

FDA / CBER / OCTGT / DCEPT Clinical Review Teams Oncology Peter Bross (TL) Bindu George (TL) Chaohong Fan Sadhana Kaul Robert Quan Le Lydia Martynec David Maybee Olumide Olajide (fellow) Donna Przepiorka Kevin Shannon TL = Team Leader General Internal Medicine Changting Haudenschild (TL) Bruce Schneider (TL) Mark Borigini John Hyde Agnes Lim Steven Winitsky Rachel Witten Lei Xu Michael Yao Yao-Yao Zhu

FDA IND Review: Regulations and Challenges Wilson W. Bryan, M.D. FDA / CBER / OCTGT wilson.bryan@fda.hhs.gov Workshop on Cell and Gene Therapy Clinical Trials in Pediatric Populations North Bethesda, Maryland November 2, 2010